BACKGROUND: Performing a restaging work-up with magnetic resonance imaging (MRI) and (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)F-FDG PET/CT) can provide information about the effects that are related to preoperative concurrent chemoradiotherapy (CCRT). The purpose of the present study was to investigate the accuracy of MRI and (18)F-FDG PET/CT for restaging after preoperative CCRT for rectal cancer. METHODS: Between April 2005 and February 2006, 30 patients with histologically proven rectal adenocarcinoma were included in this study. Pelvic MRI and (18)F-FDG PET/CT were performed to clinically restage the tumor after CCRT. The results of the pathologic staging were correlated with those of the MRI and (18)F-FDG PET/CT after CCRT. Two patients underwent transanal endoscopic microsurgery after CCRT, and they were excluded when the N category was evaluated. RESULTS: The overall accuracy of MRI for the T category was 67% (kappa = 0.422, P = 0.003), whereas overstaging and understaging occurred in 30 and 3% of the patients, respectively. For the N category, accurate staging was noted in 75% (kappa = 0.410, P = 0.030) of all the patients, whereas 14% were overstaged and 11% were understaged. The overall accuracy rates for the T and N categories with performing (18)F-FDG PET/CT were 60% (kappa = 0.372, P = 0.004) and 71% (kappa = 0.097, P = 0.549), respectively. While MRI could not predict any patient who showed a pathologic complete response, (18)F-FDG PET/CT predicted three of the four patients who showed a pathologic complete response after preoperative CCRT. Furthermore, (18)F-FDG PET/CT identified distant metastases with an accuracy rate of 97%. CONCLUSIONS: For restaging patients with rectal cancer after preoperative CCRT, MRI is a useful diagnostic modality to predict both the T and N categories. (18)F-FDG PET/CT is helpful in predicting a pathologic complete response and in finding metastasis after preoperative CCRT.
BACKGROUND: Performing a restaging work-up with magnetic resonance imaging (MRI) and (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography ((18)F-FDG PET/CT) can provide information about the effects that are related to preoperative concurrent chemoradiotherapy (CCRT). The purpose of the present study was to investigate the accuracy of MRI and (18)F-FDG PET/CT for restaging after preoperative CCRT for rectal cancer. METHODS: Between April 2005 and February 2006, 30 patients with histologically proven rectal adenocarcinoma were included in this study. Pelvic MRI and (18)F-FDG PET/CT were performed to clinically restage the tumor after CCRT. The results of the pathologic staging were correlated with those of the MRI and (18)F-FDG PET/CT after CCRT. Two patients underwent transanal endoscopic microsurgery after CCRT, and they were excluded when the N category was evaluated. RESULTS: The overall accuracy of MRI for the T category was 67% (kappa = 0.422, P = 0.003), whereas overstaging and understaging occurred in 30 and 3% of the patients, respectively. For the N category, accurate staging was noted in 75% (kappa = 0.410, P = 0.030) of all the patients, whereas 14% were overstaged and 11% were understaged. The overall accuracy rates for the T and N categories with performing (18)F-FDG PET/CT were 60% (kappa = 0.372, P = 0.004) and 71% (kappa = 0.097, P = 0.549), respectively. While MRI could not predict any patient who showed a pathologic complete response, (18)F-FDG PET/CT predicted three of the four patients who showed a pathologic complete response after preoperative CCRT. Furthermore, (18)F-FDG PET/CT identified distant metastases with an accuracy rate of 97%. CONCLUSIONS: For restaging patients with rectal cancer after preoperative CCRT, MRI is a useful diagnostic modality to predict both the T and N categories. (18)F-FDG PET/CT is helpful in predicting a pathologic complete response and in finding metastasis after preoperative CCRT.
Authors: M H Whiteford; H M Whiteford; L F Yee; O A Ogunbiyi; F Dehdashti; B A Siegel; E H Birnbaum; J W Fleshman; I J Kodner; T E Read Journal: Dis Colon Rectum Date: 2000-06 Impact factor: 4.585
Authors: R J Zagoria; C A Schlarb; D J Ott; R I Bechtold; N T Wolfman; E S Scharling; M Y Chen; B W Loggie Journal: J Surg Oncol Date: 1997-04 Impact factor: 3.454
Authors: H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price Journal: Eur J Cancer Date: 1999-12 Impact factor: 9.162
Authors: H Abdel-Nabi; R J Doerr; D M Lamonica; V R Cronin; P J Galantowicz; G M Carbone; M B Spaulding Journal: Radiology Date: 1998-03 Impact factor: 11.105
Authors: Jose G Guillem; Harvey G Moore; Timothy Akhurst; David S Klimstra; Leyo Ruo; Madhu Mazumdar; Bruce D Minsky; Leonard Saltz; W Douglas Wong; Steven Larson Journal: J Am Coll Surg Date: 2004-07 Impact factor: 6.113
Authors: C Brendle; N F Schwenzer; H Rempp; H Schmidt; C Pfannenberg; C la Fougère; K Nikolaou; C Schraml Journal: Eur J Nucl Med Mol Imaging Date: 2015-07-31 Impact factor: 9.236
Authors: Wijnand J Alberda; Helene P N Dassen; Roy S Dwarkasing; François E J A Willemssen; Anne E M van der Pool; Johannes H W de Wilt; Jacobus W A Burger; Cornelis Verhoef Journal: Int J Colorectal Dis Date: 2012-09-22 Impact factor: 2.571